273 related articles for article (PubMed ID: 36387240)
21. Prognostic Value of Genomic Instability of m
Li R; Li JP; Liu TT; Huo C; Yao J; Ji XL; Qu YQ
Front Cell Dev Biol; 2022; 10():707405. PubMed ID: 35309906
[No Abstract] [Full Text] [Related]
22. A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma.
Ma S; Zhu J; Wang M; Zhu J; Wang W; Xiong Y; Jiang R; Seetharamu N; Abrão FC; Puthamohan VM; Liu L; Jiang T
Transl Lung Cancer Res; 2022 Oct; 11(10):2079-2093. PubMed ID: 36386454
[TBL] [Abstract][Full Text] [Related]
23. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
24. Disulfidptosis‑related lncRNA prognosis model to predict survival therapeutic response prediction in lung adenocarcinoma.
Sun X; Li J; Gao X; Huang Y; Pang Z; Lv L; Li H; Liu H; Zhu L
Oncol Lett; 2024 Aug; 28(2):342. PubMed ID: 38855504
[TBL] [Abstract][Full Text] [Related]
25. Characterization of a ferroptosis and iron-metabolism related lncRNA signature in lung adenocarcinoma.
Yao J; Chen X; Liu X; Li R; Zhou X; Qu Y
Cancer Cell Int; 2021 Jul; 21(1):340. PubMed ID: 34217273
[TBL] [Abstract][Full Text] [Related]
26. Competitive endogenous RNA network identifies four long non-coding RNA signature as a candidate prognostic biomarker for lung adenocarcinoma.
Hu J; Wang T; Chen Q
Transl Cancer Res; 2019 Aug; 8(4):1046-1064. PubMed ID: 35116848
[TBL] [Abstract][Full Text] [Related]
27. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature.
Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G
J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988
[TBL] [Abstract][Full Text] [Related]
28. Prognostic model and immunotherapy prediction based on molecular chaperone-related lncRNAs in lung adenocarcinoma.
Xu Y; Tao T; Li S; Tan S; Liu H; Zhu X
Front Genet; 2022; 13():975905. PubMed ID: 36313456
[No Abstract] [Full Text] [Related]
29. Construction of an immune-related lncRNA signature pair for predicting oncologic outcomes and the sensitivity of immunosuppressor in treatment of lung adenocarcinoma.
Zhuang J; Chen Z; Chen Z; Chen J; Liu M; Xu X; Liu Y; Yang S; Hu Z; He F
Respir Res; 2022 May; 23(1):123. PubMed ID: 35562727
[TBL] [Abstract][Full Text] [Related]
30. A neutrophil extracellular traps-associated lncRNA signature predicts the clinical outcomes in patients with lung adenocarcinoma.
Ding W; Li B; Zhang Y; He L; Su J
Front Genet; 2022; 13():1047231. PubMed ID: 36419832
[No Abstract] [Full Text] [Related]
31. Development and validation of a DNA damage repair-related gene-based prediction model for the prognosis of lung adenocarcinoma.
Qin C; Fan X; Sai X; Yin B; Zhou S; Addeo A; Bian T; Yu H
J Thorac Dis; 2023 Dec; 15(12):6928-6945. PubMed ID: 38249902
[TBL] [Abstract][Full Text] [Related]
32. Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis.
Zhu M; Zeng Q; Fan T; Lei Y; Wang F; Zheng S; Wang X; Zeng H; Tan F; Sun N; Xue Q; He J
Front Immunol; 2022; 13():783495. PubMed ID: 35222371
[TBL] [Abstract][Full Text] [Related]
33. An Immune-Related lncRNA Expression Profile to Improve Prognosis Prediction for Lung Adenocarcinoma: From Bioinformatics to Clinical Word.
Zhang B; Wang R; Li K; Peng Z; Liu D; Zhang Y; Zhou L
Front Oncol; 2021; 11():671341. PubMed ID: 33968781
[TBL] [Abstract][Full Text] [Related]
34. Construction of a cancer-associated fibroblasts-related long non-coding RNA signature to predict prognosis and immune landscape in pancreatic adenocarcinoma.
Ye Y; Zhao Q; Wu Y; Wang G; Huang Y; Sun W; Zhang M
Front Genet; 2022; 13():989719. PubMed ID: 36212154
[No Abstract] [Full Text] [Related]
35. Construction of a Ferroptosis-Related Long Non-coding RNA Prognostic Signature and Competing Endogenous RNA Network in Lung Adenocarcinoma.
Fei X; Hu C; Wang X; Lu C; Chen H; Sun B; Li C
Front Cell Dev Biol; 2021; 9():751490. PubMed ID: 34820377
[TBL] [Abstract][Full Text] [Related]
36. Identification and Validation of Immune-Related LncRNA Prognostic Signature for Lung Adenocarcinoma.
Wu G; Wang Q; Zhu T; Fu L; Li Z; Wu Y; Zhang C
Front Genet; 2021; 12():681277. PubMed ID: 34306024
[TBL] [Abstract][Full Text] [Related]
37. Construction and Validation of a Novel Ferroptosis-Related lncRNA Signature to Predict Prognosis in Colorectal Cancer Patients.
Zhang W; Fang D; Li S; Bao X; Jiang L; Sun X
Front Genet; 2021; 12():709329. PubMed ID: 34777458
[No Abstract] [Full Text] [Related]
38. Development and Validation of Lactate Metabolism-Related lncRNA Signature as a Prognostic Model for Lung Adenocarcinoma.
Mai S; Liang L; Mai G; Liu X; Diao D; Cai R; Liu L
Front Endocrinol (Lausanne); 2022; 13():829175. PubMed ID: 35422758
[TBL] [Abstract][Full Text] [Related]
39. Construction of an Immune-Related Six-lncRNA Signature to Predict the Outcomes, Immune Cell Infiltration, and Immunotherapy Response in Patients With Hepatocellular Carcinoma.
Zhou P; Lu Y; Zhang Y; Wang L
Front Oncol; 2021; 11():661758. PubMed ID: 34277410
[TBL] [Abstract][Full Text] [Related]
40. Development of a copper metabolism-related gene signature in lung adenocarcinoma.
Chang W; Li H; Zhong L; Zhu T; Chang Z; Ou W; Wang S
Front Immunol; 2022; 13():1040668. PubMed ID: 36524120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
